

# Triazolo[4,5-*d*]pyrimidines. IX.<sup>1)</sup> Reactions of 5-Chloro- and 5-(Methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines with *C*-Nucleophiles

Ken-ichi TANJI,\* Katsuhisa YAMAMOTO and Takeo HIGASHINO

School of Pharmaceutical Sciences, University of Shizuoka, 2-2-1 Oshika, Shizuoka 422, Japan. Received November 29, 1988

The nucleophilic substitution of 5-(methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (2) with potassium cyanide proceeded smoothly to give 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-carbonitrile (6), but the same reaction did not take place in the case of 5-chloro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (1).

Compounds 1 and 2 reacted with ethyl cyanoacetate in the presence of sodium hydride in tetrahydrofuran, giving ethyl  $\alpha$ -cyano-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-acetate (7). When acetone was used as a ketone, it added across the C<sup>7</sup>,N<sup>6</sup>-double bond, giving 7-acetonyl-5-chloro-6,7-dihydro- (8a) and 7-acetonyl-6,7-dihydro-5-(methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (8b), respectively, although the yields were low.

The reaction of 1 with Grignard reagents resulted in the formation of addition products such as 7-alkylated 5-chloro-6,7-dihydro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (9a—e). The substitution of the methylsulfonyl group of 2 with Grignard reagents proceeded to give the corresponding 5-alkylated 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (11a—e).

**Keywords** 5-chloro-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine; 5-(methylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine; nucleophilic substitution; Grignard reagent; addition reaction; *C*-nucleophile

We reported that chloro<sup>2)</sup> and *p*-tolylsulfonyl groups<sup>2)</sup> at the 7-position of the 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine ring could be replaced by *C*-nucleophiles, resulting in the introduction of functionalized carbons at the 7-position. However, little work has been reported on introducing a functionalized carbon at the 5-position of the 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine ring. In the present paper, we describe the reactions of 5-chloro-(1) and 5-(methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (2) with *C*-nucleophiles.

Compound 2 was easily prepared by the substitution of 1 with sodium methyl sulfide in dimethylformamide (DMF), followed by oxidation with potassium permanganate (KMnO<sub>4</sub>) in acetic acid (AcOH).

It was reported<sup>3)</sup> that the reaction of 1 with *O*-, *N*-, and *S*-nucleophiles gave 5-substituted 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines. Similarly, compound 2 reacted with sodium methoxide and butylamine to afford 5-methoxy- (4) and 5-butylamino-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (5), respectively.

Then we investigated the reactions of 1 and 2 with *C*-nucleophiles. We reported<sup>2)</sup> that the chlorine atom at the 7-position of the 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine ring was replaced by potassium cyanide (KCN) in DMF, giving 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-7-carbonitrile. However, similar substitution did not take place at the 5-position. On the other hand, nucleophilic substitution of the methylsulfonyl group at the 5-position with KCN in DMF

proceeded smoothly at room temperature, yielding 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-carbonitrile (6).

It was reported<sup>2)</sup> that the reactions of 7-chloro- and 7-(*p*-tolylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine with active methylene compounds and ketones in the presence of sodium hydride (NaH) in DMF gave the corresponding 7-substituted 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine. Similarly, in the reaction with ethyl cyanoacetate as an active methylene compound in the presence of NaH in tetrahydrofuran (THF), compounds 1 and 2 underwent substitution, giving ethyl  $\alpha$ -cyano-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-acetate (7). On the other hand, application of this nucleophilic substitution to 1 and 2 with acetone as a ketone under the same conditions did not give the anticipated acetonyl compound. However, use of potassium hydroxide (KOH) as a base and dimethyl sulfoxide (DMSO) as a solvent instead of NaH and THF gave the addition products across the C<sup>7</sup>, N<sup>6</sup>-double bond, 7-acetonyl-5-chloro-6,7-dihydro- (8a) and 7-acetonyl-6,7-dihydro-5-(methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (8b), respectively, although the yields were low.

We reported<sup>4)</sup> that Grignard reagents added to the C<sup>7</sup>, N<sup>6</sup>-double bond of 3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine, giving corresponding 7-alkylated 6,7-dihydro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines. Some work has been reported on the reaction of halogenated *N*-heteroarenes with Grignard reagents in the absence of metal






Chart 1



phosphine complex<sup>5)</sup> catalysts. Thus, we examined the reaction of **1** with Grignard reagents.

When a solution of **1** and methylmagnesium iodide in THF was refluxed for 2 h, the addition of methylmagnesium iodide across the C<sup>7</sup>, N<sup>6</sup>-double bond of **1** was found to occur, giving 5-chloro-6,7-dihydro-7-methyl-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (**9a**). A similar addition proceeded in the case of the reaction of **1** with ethyl-, phenyl-, benzyl-, and phenethylmagnesium bromide under the same conditions, giving the corresponding 7-alkylated 5-chloro-6,7-dihydro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (**9b–e**). Compounds **9a–e** were easily aromatized to 7-alkylated 5-chloro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines (**10a–e**) by oxidation with 2,3-dichloro-4,5-dicyano-*p*-benzoquinone (DDQ) in THF. It appeared from the above results that **1** undergoes addition of Grignard reagents to the C<sup>7</sup>, N<sup>6</sup>-double bond rather than nucleophilic substitution of the chlorine atom at the 5-position.

It is well known that sulfonyl groups of pyridine<sup>6)</sup> and quinoline<sup>7)</sup> rings are replaced by Grignard reagents. Thus, we investigated the reaction of **2** with Grignard reagents.

TABLE I. Yields, Melting Points, and Elemental Analysis for **9** and **10**

Compd.	Yield (%)	mp (°C)	Formula	Analysis (%)		
				Calcd	Found	
				C	H	N
<b>9a</b>	87	190–191 <sup>a)</sup>	C <sub>11</sub> H <sub>10</sub> ClN <sub>5</sub>	53.34 (53.27)	4.07 (4.03)	28.27 (28.20)
<b>9b</b>	80	148–150 <sup>b)</sup>	C <sub>12</sub> H <sub>12</sub> ClN <sub>5</sub>	55.07 (55.29)	4.62 (4.62)	26.76 (26.80)
<b>9c</b>	76	158–161 <sup>b)</sup>	C <sub>16</sub> H <sub>12</sub> ClN <sub>5</sub>	62.04 (62.03)	3.90 (3.90)	22.61 (22.39)
<b>9d</b>	73	172–173 <sup>a)</sup>	C <sub>17</sub> H <sub>14</sub> ClN <sub>5</sub>	63.06 (62.78)	4.36 (4.35)	21.62 (21.38)
<b>9e</b>	76	100–102 <sup>b)</sup>	C <sub>18</sub> H <sub>16</sub> ClN <sub>5</sub>	64.00 (64.25)	4.77 (4.78)	20.73 (20.61)
<b>10a</b>	88	124 <sup>b)</sup>	C <sub>11</sub> H <sub>8</sub> ClN <sub>5</sub>	53.78 (54.08)	3.28 (3.33)	28.51 (28.68)
<b>10b</b>	90	114–115 <sup>b)</sup>	C <sub>12</sub> H <sub>10</sub> ClN <sub>5</sub>	55.50 (55.44)	3.88 (3.89)	26.97 (26.94)
<b>10c</b>	68	183–187 <sup>b)</sup>	C <sub>16</sub> H <sub>10</sub> ClN <sub>5</sub>	62.44 (62.48)	3.28 (3.30)	22.89 (22.63)
<b>10d</b>	50	110–111 <sup>b)</sup>	C <sub>17</sub> H <sub>12</sub> ClN <sub>5</sub>	63.46 (63.63)	3.76 (3.83)	21.76 (21.76)
<b>10e</b>	86	99–100 <sup>b)</sup>	C <sub>18</sub> H <sub>14</sub> ClN <sub>5</sub>	64.38 (64.60)	4.20 (4.26)	20.86 (20.49)

a) Recrystallized from benzene. b) Recrystallized from petroleum benzene.

TABLE II. Yields, Melting Points, and Elemental Analysis for **11** and **12**

Compd.	Yield (%)	mp (°C)	Formula	Analysis (%)		
				Calcd	Found	
				C	H	N
<b>11a</b>	76	155–157 <sup>a)</sup>	C <sub>11</sub> H <sub>9</sub> N <sub>5</sub>	62.55 (62.69)	4.30 (4.36)	33.16 (33.11)
<b>11b</b>	69	75–77 <sup>b)</sup>	C <sub>12</sub> H <sub>11</sub> N <sub>5</sub>	63.98 (63.99)	4.92 (4.95)	31.09 (30.88)
<b>11c</b>	35	131–134 <sup>b)</sup>	C <sub>16</sub> H <sub>11</sub> N <sub>5</sub>	70.31 (70.55)	4.06 (4.05)	25.63 (25.54)
<b>11d</b>	24	106–107 <sup>a)</sup>	C <sub>17</sub> H <sub>13</sub> N <sub>5</sub>	71.06 (71.20)	4.56 (4.54)	24.38 (24.42)
<b>11e</b>	55	105–107 <sup>a)</sup>	C <sub>18</sub> H <sub>15</sub> N <sub>5</sub>	71.74 (71.82)	5.02 (5.09)	23.24 (22.88)
<b>12c</b>	12	176–177 <sup>c)</sup>	C <sub>17</sub> H <sub>15</sub> N <sub>5</sub> O <sub>2</sub> S	57.78 (57.48)	4.28 (4.32)	19.82 (19.51)

a) Recrystallized from petroleum benzene–benzene. b) Recrystallized from petroleum benzene. c) Recrystallized from chloroform.

When a solution of **2** and methylmagnesium iodide in THF was stirred at room temperature for 2 h, the substitution proceeded to give 5-methyl-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (**11a**). Similarly, **2** reacted with ethyl-, benzyl-, and phenethylmagnesium bromide to give **11b**, **d**, **e**, respectively. On the other hand, in the case of the reaction with phenylmagnesium bromide under the same conditions, both addition across the C<sup>7</sup>, N<sup>6</sup>-double bond and substitution of the methylsulfonyl group at the 5-position occurred, giving 6,7-dihydro-3,7-diphenyl-5-(methylsulfonyl)-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (**12c**) and 3,5-diphenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (**11c**), respectively.

We concluded that the methylsulfonyl group at the 5-position of the 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine ring was easily substituted with C-nucleophiles, that is, potassium

cyanide, the carbanion of ethyl cyanoacetate, and Grignard reagents, giving the corresponding 5-substituted 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidines. The substitution of the methylsulfonyl group in **2** with *C*-nucleophiles provides a useful method for the introduction of functionalized carbons at the 5-position of the 3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine ring.

### Experimental

All melting points are uncorrected. Infrared (IR) spectra were measured with a Jasco A-102 diffraction grating IR spectrometer. Proton nuclear magnetic resonance (<sup>1</sup>H-NMR) spectra were taken at 60 MHz and 23 °C with a Hitachi R-24B high-resolution <sup>1</sup>H-NMR spectrometer. Chemical shifts are expressed in parts per million (ppm) downfield from tetramethylsilane as an internal standard. The following abbreviations are used: s=singlet, d=doublet, t=triplet, br=broad, q=quartet, m=multiplet.

**5-(Methylthio)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (3)** A solution of **1**<sup>3</sup> (2.5 g, 12 mmol) and 15% aqueous NaOMe (10 ml, 22 ml) in DMF (5 ml) was stirred at 60 °C for 1 h. The reaction mixture was poured into water and extracted with benzene. The crude product obtained from the benzene extract was purified by SiO<sub>2</sub> column chromatography using petroleum benzine–benzene to give **3** as colorless needles, mp 119–120 °C. Yield 2 g (70%). *Anal.* Calcd for C<sub>11</sub>H<sub>9</sub>N<sub>3</sub>S: C, 54.30; H, 3.73; N, 28.79. Found: C, 54.63; H, 3.72; N, 28.53. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 2.66 (3H, s, SCH<sub>3</sub>), 7.37–7.75 (3H, m, N<sup>3</sup>-Ph), 8.24–8.31 (2H, m, N<sup>3</sup>-Ph), 9.28 (1H, s, C<sup>7</sup>-H).

**5-(Methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (2)** A solution of KMnO<sub>4</sub> (2.6 g, 16.4 mmol) in H<sub>2</sub>O (50 ml) was added to a solution of **3** (2.0 g, 8.2 mmol) in AcOH (100 ml). The mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with H<sub>2</sub>O, made alkaline with Na<sub>2</sub>CO<sub>3</sub>, and extracted with benzene. The crude product obtained from the benzene extract was purified by SiO<sub>2</sub> column chromatography using benzene–CHCl<sub>3</sub> (1:1) as an eluant and recrystallized from benzene–CHCl<sub>3</sub> to give **2** as colorless needles, mp 149–150 °C. Yield 1.46 g (65%). *Anal.* Calcd for C<sub>11</sub>H<sub>9</sub>N<sub>3</sub>O<sub>2</sub>S: C, 48.00; H, 3.30; N, 25.44. Found: C, 48.47; H, 3.33; N, 25.27. IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 1120, 1305 (SO<sub>2</sub>). <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 3.45 (3H, s, SO<sub>2</sub>CH<sub>3</sub>), 7.41–7.67 (3H, m, N<sup>3</sup>-Ph), 8.08–8.24 (2H, m, N<sup>3</sup>-Ph), 9.64 (1H, s, C<sup>7</sup>-H).

**5-Methoxy-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (4)** A solution of **2** (150 mg, 0.55 mmol) and NaOMe (30 mg, 0.55 mmol) in MeOH (15 ml) was stirred at room temperature for 1 h. The solvent was removed under reduced pressure. The residue was diluted with H<sub>2</sub>O and extracted with CHCl<sub>3</sub>. The crude product obtained from the CHCl<sub>3</sub> extract was recrystallized from petroleum benzine–benzene to give **4** as colorless needles, mp 94–95 °C (lit.<sup>31</sup> mp 98–99 °C). Yield 120 mg (97%). <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 4.14 (3H, s, OCH<sub>3</sub>), 7.38–7.65 (3H, m, N<sup>3</sup>-Ph), 8.10–8.28 (2H, m, N<sup>3</sup>-Ph), 9.41 (1H, s, C<sup>7</sup>-H).

**5-Butylamino-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (5)** A solution of **2** (150 mg, 0.55 mmol) and butylamine (41 mg, 0.55 mmol) in CHCl<sub>3</sub> (5 ml) was refluxed for 30 min. The mixture was diluted with H<sub>2</sub>O and extracted with CHCl<sub>3</sub>. The CHCl<sub>3</sub> extract was washed with 2*N* HCl. The crude product obtained from the CHCl<sub>3</sub> extract was recrystallized from CHCl<sub>3</sub> to give **5** as colorless needles, mp 149–150 °C. Yield 125 mg (86%). *Anal.* Calcd for C<sub>14</sub>H<sub>16</sub>N<sub>6</sub>: C, 62.66; H, 6.02; N, 31.32. Found: C, 62.47; H, 6.03; N, 31.22. IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 3250 (NH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 0.84–1.17 (3H, m, NH(CH<sub>2</sub>)<sub>3</sub>CH<sub>3</sub>), 1.28–1.78 (4H, m, NHCH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>), 3.35–3.66 (2H, m, NHCH<sub>2</sub>(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>), 5.62–6.18 (1H, br, NH), 7.25–7.61 (3H, m, N<sup>3</sup>-Ph), 8.05–8.21 (2H, m, N<sup>3</sup>-Ph), 8.95 (1H, s, C<sup>7</sup>-H).

**3-Phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-carbonitrile (6)** A solution of **2** (200 mg, 0.72 mmol) and KCN (95 mg, 1.44 mmol) in DMF (5 ml) was stirred at room temperature for 1.5 h. The mixture was diluted with H<sub>2</sub>O and extracted with benzene. The crude product obtained from the benzene extract was recrystallized from benzene to give **6** as a yellow solid, mp 172–173 °C. Yield 156 mg (96%). *Anal.* Calcd for C<sub>11</sub>H<sub>6</sub>N<sub>6</sub>: C, 59.45; H, 2.72; N, 37.82. Found: C, 59.65; H, 2.79; N, 38.00. <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 7.36–7.79 (3H, m, N<sup>3</sup>-Ph), 7.94–8.33 (2H, m, N<sup>3</sup>-Ph), 9.63 (1H, s, C<sup>7</sup>-H).

**Ethyl α-Cyano-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine-5-acetate (7)** 1) A solution of **1** (116 mg, 0.5 mmol), ethyl cyanoacetate (113 mg, 1 mmol), and 60% (in oil) NaH (40 mg, 1 mmol) in DMF (3 ml) was stirred at room temperature for 3 h. The mixture was diluted with H<sub>2</sub>O, neutralized with AcOH, and extracted with CHCl<sub>3</sub>. The crude product obtained from the CHCl<sub>3</sub> extract was purified by SiO<sub>2</sub> column

chromatography using CHCl<sub>3</sub>–MeOH (100:1) and recrystallized from benzene–MeOH to give **7** as pale yellow needles, mp 280–282 °C. Yield 105 mg (62%). *Anal.* Calcd for C<sub>15</sub>H<sub>12</sub>N<sub>6</sub>O<sub>2</sub>·H<sub>2</sub>O: C, 55.21; H, 4.32; N, 25.76. Found: C, 55.41; H, 3.95; N, 26.10. IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 1695 (C=O), 2140 (CN). <sup>1</sup>H-NMR (DMSO-*d*<sub>6</sub>): 1.31 (3H, t, *J* = 7.0 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 4.23 (2H, q, *J* = 7.0 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 7.38–7.89 (6H, m, N<sup>3</sup>-Ph and CH<sub>2</sub>CN), 8.82 (1H, s, C<sup>7</sup>-H).

2) A mixture of **2** (200 mg, 0.73 mmol), ethyl cyanoacetate (165 mg, 1.46 mmol), 60% (in oil) NaH (58 mg, 1.46 mmol), and DMF (5 ml) was stirred at room temperature for 3 h. The same work-up of the reaction mixture as described for **7** under item 1) gave **7** in 93% yield (210 mg).

**7-Acetyl-5-chloro-6,7-dihydro-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (8a)** A solution of **1** (232 mg, 1 mmol), acetone (87 mg, 1.5 mmol), and KOH (86 mg, 1.5 mmol) in DMSO (5 ml) was stirred at 40 °C for 5 h. The reaction mixture was diluted with H<sub>2</sub>O, neutralized with AcOH, and extracted with CHCl<sub>3</sub>. The crude product obtained from the CHCl<sub>3</sub> extract was purified by SiO<sub>2</sub> column chromatography. The fraction eluted from benzene gave **1**. Recovery, 35 mg (15%). The fraction eluted from CHCl<sub>3</sub> gave **8a** as pale yellow needles, mp 192–193 °C. Yield 26 mg (9%). *Anal.* Calcd for C<sub>13</sub>H<sub>13</sub>ClN<sub>5</sub>O: C, 53.70; H, 4.51; N, 24.09. Found: C, 53.98; H, 4.18; N, 24.19. IR  $\nu_{\text{max}}^{\text{KBr}}$  cm<sup>-1</sup>: 1690 (C=O), 3200 (NH). <sup>1</sup>H-NMR (CDCl<sub>3</sub>): 2.22 (3H, s, CH<sub>3</sub>COCH<sub>3</sub>), 3.09 (1H, d, d, *J* = 19.0, 2.4 Hz, CH<sub>2</sub>COCH<sub>3</sub>), 3.48 (1H, d, d, *J* = 19.0, 10.0 Hz, CH<sub>2</sub>COCH<sub>3</sub>), 5.59 (1H, d, d, *J* = 2.4, 10.0 Hz, C<sup>7</sup>-H), 6.34–6.66 (1H, br, NH), 7.24–7.50 (3H, m, N<sup>3</sup>-Ph), 7.62–7.88 (2H, m, N<sup>3</sup>-Ph).

**7-Acetyl-6,7-dihydro-5-(methylsulfonyl)-3-phenyl-3*H*-1,2,3-triazolo[4,5-*d*]pyrimidine (8b)** A solution of **2** (150 mg, 0.55 mmol), acetone (47 mg, 0.83 mmol), and KOH (46 mg, 0.83 mmol) in DMSO (5 ml) was stirred at room temperature for 3 h. The mixture was diluted with H<sub>2</sub>O, neutralized with AcOH, and extracted with CHCl<sub>3</sub>. The crude product

TABLE III. IR and <sup>1</sup>H-NMR Spectral Data for **9a–e**

Compd.	IR $\nu_{\text{max}}^{\text{KBr}}$ (cm <sup>-1</sup> )	<sup>1</sup> H-NMR (CDCl <sub>3</sub> ) δ
<b>9a</b>	3320 (NH)	1.68 (3H, d, <i>J</i> = 7.0 Hz, CH <sub>3</sub> ), 5.30 (1H, dq, <i>J</i> = 7.0 Hz, <i>J</i> = 3.8 Hz, C <sup>7</sup> -H), 6.51–6.79 (1H, br, NH), 7.29–7.65 (3H, m, N <sup>3</sup> -Ph), 7.80–7.97 (2H, m, N <sup>3</sup> -Ph)
<b>9b</b>	3160 (NH)	1.02 (3H, t, <i>J</i> = 7.0 Hz, CH <sub>2</sub> CH <sub>3</sub> ), 1.73–2.21 (2H, m, CH <sub>2</sub> CH <sub>3</sub> ), 5.10 (1H, t, <i>J</i> = 4.0 Hz, C <sup>7</sup> -H), 6.45–6.90 (1H, br, NH), 7.23–7.56 (3H, m, N <sup>3</sup> -Ph), 7.70–7.79 (2H, m, N <sup>3</sup> -Ph)
<b>9c</b>	3150 (NH)	5.99 (1H, d, <i>J</i> = 2.0 Hz, C <sup>7</sup> -H), 6.18–6.91 (1H, br, NH), 7.21–7.55 (8H, m, N <sup>3</sup> -Ph and C <sup>7</sup> -H), 7.71–7.93 (2H, m, N <sup>3</sup> -Ph)
<b>9d</b>	3150 (NH)	3.90 (1H, dd, <i>J</i> = 14.0, 3.2 Hz, CH <sub>2</sub> Ph), 3.47 (1H, dd, <i>J</i> = 14.0, 8.8 Hz, CH <sub>2</sub> Ph), 5.42 (1H, dd, <i>J</i> = 3.2, 8.8 Hz, C <sup>7</sup> -H), 6.09–6.35 (1H, br, NH), 6.96–7.60 (8H, m, N <sup>3</sup> -Ph and CH <sub>2</sub> Ph), 7.67–7.89 (2H, m, N <sup>3</sup> -Ph)
<b>9e</b>	3200 (NH)	2.06–2.97 (4H, m, CH <sub>2</sub> CH <sub>2</sub> Ph), 5.00–5.28 (1H, m, C <sup>7</sup> -H), 6.25–6.50 (1H, br, NH), 6.96–7.55 (8H, m, N <sup>3</sup> -Ph and C <sub>2</sub> H <sub>4</sub> Ph), 7.67–7.89 (2H, m, N <sup>3</sup> -Ph)

TABLE IV. <sup>1</sup>H-NMR Spectral Data for **10a–e**

Compd.	<sup>1</sup> H-NMR (CDCl <sub>3</sub> ) δ
<b>10a</b>	2.88 (3H, s, CH <sub>3</sub> ), 7.20–7.65 (3H, m, N <sup>3</sup> -Ph), 7.83–8.13 (2H, m, N <sup>3</sup> -Ph)
<b>10b</b>	1.54 (3H, t, <i>J</i> = 7.0 Hz, CH <sub>2</sub> CH <sub>3</sub> ), 3.38 (2H, q, <i>J</i> = 7.0 Hz, CH <sub>2</sub> CH <sub>3</sub> ), 7.35–7.79 (3H, m, N <sup>3</sup> -Ph), 7.96–8.34 (2H, m, N <sup>3</sup> -Ph)
<b>10c</b>	7.30–7.69 (5H, m, C <sup>7</sup> -Ph), 7.97–8.30 (3H, m, N <sup>3</sup> -Ph), 8.74–8.99 (2H, m, N <sup>3</sup> -Ph)
<b>10d</b>	4.56 (2H, s, CH <sub>2</sub> Ph), 7.07–7.65 (8H, m, N <sup>3</sup> -Ph and CH <sub>2</sub> Ph), 7.88–8.15 (2H, m, N <sup>3</sup> -Ph)
<b>10e</b>	3.12–3.82 (4H, m, CH <sub>2</sub> CH <sub>2</sub> Ph), 7.24 (5H, s, CH <sub>2</sub> CH <sub>2</sub> Ph), 7.38–7.80 (3H, m, N <sup>3</sup> -Ph), 7.97–8.28 (2H, m, N <sup>3</sup> -Ph)

TABLE V. IR and  $^1\text{H}$ -NMR Spectral Data for **11** and **12**

Compd.	IR $\nu_{\text{max}}^{\text{KBr}}$ ( $\text{cm}^{-1}$ )	$^1\text{H}$ -NMR ( $\text{CDCl}_3$ ) $\delta$
<b>11a</b>		2.88 (3H, s, $\text{CH}_3$ ), 7.30—7.78 (3H, m, $\text{N}^3\text{-Ph}$ ), 8.01—8.25 (2H, m, $\text{N}^3\text{-Ph}$ ), 9.38 (1H, s, $\text{C}^7\text{-H}$ )
<b>11b</b>		1.46 (3H, t, $J=7.0$ Hz, $\text{CH}_2\text{CH}_3$ ), 3.17 (2H, q, $J=7.0$ Hz, $\text{CH}_2\text{CH}_3$ ), 7.27—7.65 (3H, m, $\text{N}^3\text{-Ph}$ ), 8.03—8.31 (2H, m, $\text{N}^3\text{-Ph}$ ), 9.39 (1H, s, $\text{C}^7\text{-H}$ )
<b>11c</b>		7.08—7.60 (6H, m, $\text{N}^3\text{-Ph}$ and $\text{C}^5\text{-Ph}$ ), 8.02—8.42 (4H, m, $\text{N}^3\text{-Ph}$ and $\text{C}^5\text{-Ph}$ ), 9.34 (1H, s, $\text{C}^7\text{-H}$ )
<b>11d</b>		4.45 (2H, s, $\text{CH}_2\text{Ph}$ ), 7.05—7.78 (8H, m, $\text{N}^3\text{-Ph}$ and $\text{CH}_2\text{Ph}$ ), 8.00—8.43 (2H, m, $\text{N}^3\text{-Ph}$ ), 9.45 (1H, s, $\text{C}^7\text{-H}$ )
<b>11e</b>		2.71—3.80 (4H, m, $\text{CH}_2\text{CH}_2\text{Ph}$ ), 7.17 (5H, s, $\text{CH}_2\text{CH}_2\text{Ph}$ ), 7.34—7.67 (3H, m, $\text{N}^3\text{-Ph}$ ), 8.05—8.23 (2H, m, $\text{N}^3\text{-Ph}$ ), 9.42 (1H, s, $\text{C}^7\text{-H}$ )
<b>12c</b>	1130 ( $\text{SO}_2$ ) 1300 ( $\text{SO}_2$ ) 3270 (NH)	3.12 (3H, s, $\text{SO}_2\text{CH}_3$ ), 6.22 (1H, d, $J=2.0$ Hz, $\text{C}^7\text{-H}$ ), 7.22—7.50 (9H, m, $\text{N}^3\text{-Ph}$ , $\text{C}^7\text{-Ph}$ , and NH), 7.72—7.95 (2H, m, $\text{N}^3\text{-Ph}$ )

obtained from the  $\text{CHCl}_3$  extract was purified by  $\text{SiO}_2$  column chromatography using  $\text{CHCl}_3$  as an eluant and recrystallized from benzene to give **8b** as a colorless solid, mp 163—165°C. Yield 25 mg (14%). *Anal.* Calcd for  $\text{C}_{14}\text{H}_{15}\text{N}_5\text{O}_3\text{S}$ : C, 50.44; H, 4.54; N, 21.01. Found: C, 50.26; H, 4.46; N, 20.87. IR  $\nu_{\text{max}}^{\text{KBr}}$   $\text{cm}^{-1}$ : 1130, 1310 ( $\text{SO}_2$ ), 1700 ( $\text{C}=\text{O}$ ).  $^1\text{H}$ -NMR ( $\text{CDCl}_3$ ): 2.22 (3H, s,  $\text{CH}_2\text{COCH}_3$ ), 2.61—3.80 (2H, m,  $\text{CH}_2\text{COCH}_3$ ), 3.16 (3H, s,  $\text{SO}_2\text{CH}_3$ ), 5.51—5.80 (1H, br,  $\text{C}^7\text{-H}$ ), 7.25—7.66 (4H, m,  $\text{N}^3\text{-Ph}$  and NH), 7.70—8.01 (2H, m,  $\text{N}^3\text{-Ph}$ ).

**General Procedure for the Reaction of 1 with Grignard Reagents** A solution of **1** (232 mg, 1 mmol) and Grignard reagent (2 mmol) in THF

(10 ml) was refluxed for 3 h. The solvent was removed under reduced pressure. The residue was diluted with a mixture of 28%  $\text{NH}_4\text{OH}$ — $\text{NH}_4\text{Cl}$ — $\text{H}_2\text{O}$  (1:1:5) and extracted with  $\text{CHCl}_3$ . The crude product obtained from the  $\text{CHCl}_3$  extract was purified by  $\text{SiO}_2$  column chromatography using  $\text{CHCl}_3$  as an eluant and recrystallized from the appropriate solvent shown in Table I to give **9a—e**.

**General Procedure for the Oxidation of 9 with DDQ** A solution of **9** (0.47 mmol) and DDQ (0.55 mmol) in THF (4 ml) was stirred at room temperature for 2 h. The solvent was removed under reduced pressure. The residue was diluted with  $\text{H}_2\text{O}$  and extracted with  $\text{CHCl}_3$ . The crude product obtained from the  $\text{CHCl}_3$  extract was purified by  $\text{SiO}_2$  column chromatography using benzene— $\text{CHCl}_3$  (1:1) as an eluant and recrystallized from petroleum benzine—benzene to give **10a—e**.

**General Procedure for the Reaction of 2 with Grignard Reagents** A solution of **2** (275 mg, 1 mmol) and Grignard reagent (1.5 mmol) in THF (10 ml) was stirred at room temperature for 3 h. The solvent was removed under reduced pressure. The residue was diluted with a mixture of 28%  $\text{NH}_4\text{OH}$ — $\text{NH}_4\text{Cl}$ — $\text{H}_2\text{O}$  (1:1:5) and extracted with  $\text{CHCl}_3$ . The crude product obtained from the  $\text{CHCl}_3$  extract was purified by  $\text{SiO}_2$  column chromatography. The fraction eluted from benzene gave **11a—e**. The fraction from  $\text{CHCl}_3$  gave **12c**.

## References

- 1) Part VIII: T. Higashino, M. Takemoto, A. Miyashita and E. Hayashi, *Chem. Pharm. Bull.*, **33**, 1395 (1985).
- 2) T. Higashino, T. Katori, H. Kawaraya and E. Hayashi, *Chem. Pharm. Bull.*, **28**, 337 (1980).
- 3) S S Pharmaceutical Co., Ltd., Japan. Patent 5962594 (1984) [*Chem. Abstr.*, **101**, P72754 (1984)].
- 4) T. Higashino, T. Katori, S. Yoshida and E. Hayashi, *Chem. Pharm. Bull.*, **27**, 3176 (1979).
- 5) a) H. Yamanaka, K. Edo, F. Shoji, S. Konno, T. Sakamoto and M. Mizugaki, *Chem. Pharm. Bull.*, **26**, 2160 (1978); b) D. E. Bergstrom and P. A. Reday, *Tetrahedron Lett.*, **23**, 419 (1982).
- 6) N. Furukawa, M. Tsuruoka and H. Fujihara, *Heterocycles*, **24**, 3337 (1986).
- 7) E. Hayashi and T. Saito, *Yakugaku Zasshi*, **89**, 74 (1969).